Guggenheim Lifts PT on AstraZeneca PLC (AZN) to 16,000 GBp From 15,500 GBp

Core Viewpoint - AstraZeneca PLC (NASDAQ:AZN) is highlighted as a highly profitable blue chip stock, with Guggenheim raising its price target to 16,000 GBp from 15,500 GBp, maintaining a Buy rating following the company's fiscal 2025 results and investor presentations [1]. Group 1: Company Developments - AstraZeneca and Daiichi Sankyo's supplemental Biologics License Application for Enhertu has been accepted and granted Priority Review by the FDA for treating adult patients with HER2-positive breast cancer [2]. - The FDA's Priority Review designation is given to applications that may offer significant improvements over existing treatments, enhancing safety, efficacy, or patient compliance [3]. - The Prescription Drug User Fee Act date, which is the FDA's action date for regulatory decisions, is anticipated in the third quarter of 2026 [3]. Group 2: Company Overview - AstraZeneca is a biopharmaceutical company engaged in the exploration, development, manufacturing, and commercialization of prescription medicines, focusing on novel immuno-oncology treatment approaches [4].